Sibeprenlimab & Anti-APRIL in IgAN — PatSnap Eureka
Sibeprenlimab & Anti-APRIL Antibodies in IgA Nephropathy
The race to block APRIL and BAFF in IgAN has intensified. Sibeprenlimab reduced proteinuria by 47.4% versus 23.0% for placebo at 12 months — but CSL Vifor, Novartis, and AstraZeneca are filing fast and running Phase III trials. Map every patent position and clinical signal with PatSnap Eureka.
The Four-Hit Cascade: Why APRIL Is the Central Target
IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide and a leading cause of renal failure. Its pathogenesis follows the four-hit hypothesis: (1) overproduction of galactose-deficient IgA1 (Gd-IgA1), (2) generation of autoantibodies against Gd-IgA1, (3) formation of pathogenic immune complexes, and (4) mesangial deposition with subsequent complement activation and inflammation. Understanding this cascade is foundational to reading the patent landscape.
APRIL (a proliferation-inducing ligand), a cytokine of the tumor necrosis factor superfamily, plays a central role in IgAN pathogenesis by promoting IgA class-switch recombination and stimulating IgA production. APRIL signals through two receptors — TACI (transmembrane activator and calcium modulator and cyclophilin ligand interactor) and BCMA (B cell maturation antigen) — and is significantly upregulated in IgAN patients. Mucosal B cells in the gut and respiratory tract undergo class switching to IgA under the influence of APRIL and BAFF secreted by dendritic cells and epithelial cells.
Therapeutic inhibition of APRIL with monoclonal antibodies, including sibeprenlimab, offers a targeted approach to reducing Gd-IgA1 production and subsequent mesangial deposition, potentially slowing disease progression at the earliest pathogenic step. This upstream mechanism distinguishes APRIL/BAFF inhibitors from downstream approaches such as complement inhibition or hemodynamic RAAS/endothelin blockade, which are also in active development. Learn more about PatSnap's life sciences intelligence platform for tracking these converging pipelines.
Key Assignees in the Anti-APRIL/BAFF IgAN Patent Race
Multiple pharmaceutical companies have filed patent families targeting APRIL, BAFF, or both in IgA nephropathy. Each takes a distinct mechanistic and clinical approach.
Sibeprenlimab (VIS649) — Selective APRIL Blockade
Sibeprenlimab is a humanized anti-APRIL antibody that binds to a conformational epitope on APRIL's receptor-binding domain, inhibiting APRIL binding to both TACI and BCMA. Visterra patents cover subcutaneous administration every 4 or 8 weeks, dosing in patients with eGFR ≥30 ml/min/1.73m² or eGFR ≥20 ml/min/1.73m² with total proteinuria ≥1.0 g/day, and combination with ACE inhibitors, ARBs, or SGLT-2 inhibitors such as dapagliflozin. The pivotal Phase 3 trial is designated VISIONARY-IgAN.
Phase 3 — VISIONARY-IgANPovetacicept (BION-1301) — Dual APRIL + BAFF Inhibition
Povetacicept is a bispecific fusion protein targeting both APRIL and BAFF. It binds APRIL via a TACI-derived domain and BAFF via a BCMA-derived domain, providing dual cytokine inhibition that may exceed the efficacy of selective APRIL-only blockade. In Phase 2 studies in IgAN patients, povetacicept reduced proteinuria (UPCR) by approximately 65% and serum IgA by over 60% at 12 months. Novartis's patent (WO2024201249A1) covers the bispecific antibody and its use in IgAN.
Phase 3 — Dual APRIL+BAFFProprietary Anti-APRIL Antibodies — TACI/BCMA Blockade
CSL Vifor has filed two US patent applications (US20230340115A1 and US20230416399A1) covering anti-APRIL antibodies that specifically bind to APRIL and inhibit APRIL-mediated signaling, in particular inhibiting APRIL binding to TACI and BCMA. The patents describe inhibition of APRIL-mediated IgA class switch, IgA overproduction, and APRIL-mediated IgA deposition — the same upstream mechanism as sibeprenlimab, positioning CSL Vifor as a direct competitor in the selective APRIL-inhibition space.
Preclinical / Early ClinicalZigakibart — Anti-BAFF Receptor (BAFFR/BR3) Antibody
Zigakibart is a monoclonal antibody targeting the B-cell activating factor receptor (BAFFR/BR3), thereby inhibiting BAFF-mediated B cell survival and IgA class switching. Unlike direct APRIL-targeting antibodies, zigakibart acts at the receptor level, blocking the downstream effects of BAFF. In a Phase 2 trial in IgAN patients, zigakibart demonstrated meaningful reduction in proteinuria and serum IgA. AstraZeneca has also filed patents (WO2022147258A1) covering methods of treating IgAN with zigakibart.
Late-Stage ClinicalEfficacy Signals Across the Anti-APRIL/BAFF Pipeline
Comparing proteinuria reduction and mechanistic differentiation across agents in clinical development for IgA nephropathy, derived from published trial data and patent literature.
UPCR Reduction at Primary Endpoint by Agent
Sibeprenlimab (47.4%), povetacicept (~65%), and sparsentan (~49%) represent the leading efficacy signals in Phase 2/3 IgAN trials. Dual APRIL+BAFF inhibition shows higher numerical reduction.
Mechanistic Positioning of IgAN Pipeline Agents
The IgAN pipeline spans upstream cytokine blockade (APRIL/BAFF), complement inhibition, and downstream hemodynamic approaches — each targeting a different hit in the four-hit cascade.
Sibeprenlimab Combination Approaches Covered by Visterra Patents
Visterra's patent portfolio explicitly covers co-administration of sibeprenlimab with standard-of-care agents, broadening the potential treatment paradigm.
ACE Inhibitor / ARB Combination
Visterra's WO2023215516A1 covers methods comprising administering sibeprenlimab together with an angiotensin-converting enzyme inhibitor (ACE inhibitor) or angiotensin receptor blocker (ARB) as a second therapy, aligning with current IgAN standard-of-care supportive treatment guidelines.
SGLT-2 Inhibitor Combination (Dapagliflozin)
The same Visterra patent explicitly names dapagliflozin as a combination partner — a sodium glucose co-transporter 2 (SGLT-2) inhibitor — reflecting the growing evidence base for SGLT-2 inhibitors in chronic kidney disease and their potential to complement upstream IgA reduction.
Anti-APRIL Antibody Patent Families in IgAN: Assignee Overview
Seven or more assignees have active patent families targeting APRIL or BAFF signalling in IgA nephropathy, spanning large pharma, mid-size biotech, and Chinese pharmaceutical companies.
| Assignee | Drug / Programme | Mechanism | Key Patent | Stage |
|---|---|---|---|---|
| Visterra / Astellas | Sibeprenlimab (VIS649) | Selective anti-APRIL (TACI/BCMA blockade) | WO2023215516A1 | Phase 3 |
| Novartis / Chinook | Povetacicept (BION-1301) | Dual APRIL + BAFF (TACI + BCMA domains) | WO2024201249A1 | Phase 3 |
| CSL Vifor | Undisclosed anti-APRIL Ab | Selective anti-APRIL (TACI/BCMA blockade) | US20230340115A1 | Early Clinical |
| AstraZeneca | Zigakibart | Anti-BAFFR (receptor-level BAFF blockade) | WO2022147258A1 | Phase 2/3 |
| UCB Biopharma | Anti-APRIL/BAFF bispecific | Dual APRIL + BAFF bispecific antibody | WO2021214299A1 | Preclinical |
Monitor CSL Vifor's IgAN Patent Activity in Real Time
Get alerts when CSL Vifor, Novartis, or AstraZeneca file new IgAN-related patents or update clinical trial registrations.
Mechanistically Distinct Approaches Compete for the Same Patients
While APRIL and BAFF pathway inhibitors dominate the early-stage pipeline, the IgAN treatment landscape also includes mechanistically distinct agents that address later hits in the four-hit cascade. PatSnap's life sciences intelligence tools allow R&D and IP teams to track all of these converging pipelines simultaneously.
Sparsentan, a dual endothelin receptor type A and angiotensin II type 1 receptor antagonist developed by Travere Therapeutics, reduced proteinuria by approximately 49% versus irbesartan at the primary endpoint (36 weeks) in the PROTECT trial. Sparsentan has received accelerated FDA approval for IgAN based on UPCR reduction. Its mechanism differs fundamentally from APRIL/BAFF pathway inhibitors, addressing downstream hemodynamic and inflammatory effects rather than upstream IgA overproduction.
Complement inhibitors including iptacopan (factor B inhibitor, Novartis), narsoplimab (MASP-2 inhibitor), and avacopan (C5aR1 inhibitor) are in clinical development for IgAN, providing mechanistically distinct therapeutic options from APRIL/BAFF pathway blockade. These agents target complement activation by mesangial IgA immune complexes — the critical amplifier of glomerular injury that follows mesangial Gd-IgA1 deposition. According to ClinicalTrials.gov, multiple Phase 2 and Phase 3 trials are actively enrolling across these mechanistic classes. PatSnap's IP analytics platform provides landscape views across all these modalities.
The competitive field also includes targeted endothelin/RAAS combination therapy and complement inhibitors, meaning that IP teams and R&D strategists must monitor not only the APRIL/BAFF space but the entire IgAN therapeutic ecosystem to assess freedom-to-operate and white space opportunities. Explore how PatSnap customers use Eureka to navigate exactly these multi-mechanism landscapes.
Sibeprenlimab & Anti-APRIL IgAN Pipeline — Key Questions Answered
Sibeprenlimab (VIS649) is a humanized anti-APRIL antibody developed by Visterra, Inc. It blocks APRIL signaling by inhibiting APRIL binding to its receptors TACI and BCMA, thereby inhibiting APRIL-mediated IgA class switch, IgA overproduction, and APRIL-mediated IgA deposition in the mesangium.
In the Phase 2 trial, at month 12 the least-squares mean change from baseline in the ratio of urine protein to urine creatinine was −0.38 g/g (a change of −47.4%) in the 8 mg/kg sibeprenlimab group, compared with −0.20 g/g (−23.0%) in the placebo group. Mean serum IgA level was reduced by 47.0% from baseline at month 12 in the 8 mg/kg group, and the reduction in IgA was dose-dependent.
APRIL, a cytokine of the tumor necrosis factor superfamily, plays a central role in IgAN pathogenesis by promoting IgA class-switch recombination and stimulating IgA production. APRIL signals through TACI and BCMA receptors and is significantly upregulated in IgAN patients. Mucosal B cells in the gut and respiratory tract undergo class switching to IgA under the influence of APRIL and BAFF secreted by dendritic cells and epithelial cells.
Povetacicept (BION-1301) is a bispecific fusion protein targeting both APRIL and BAFF, whereas sibeprenlimab selectively targets APRIL only. Povetacicept binds APRIL via a TACI-derived domain and BAFF via a BCMA-derived domain, providing dual cytokine inhibition. In Phase 2 studies, povetacicept reduced proteinuria (UPCR) by approximately 65% and serum IgA by over 60% at 12 months, which may exceed the efficacy of selective APRIL-only blockade.
Visterra's patents describe administering sibeprenlimab together with a second therapy. The second therapy can be an angiotensin-converting enzyme inhibitor (ACE inhibitor) or angiotensin receptor blocker (ARB). In some embodiments, the second therapy is a sodium glucose co-transporter 2 (SGLT-2) inhibitor, such as dapagliflozin.
The IgA nephropathy treatment landscape includes sibeprenlimab (Visterra/Astellas), CSL Vifor's proprietary anti-APRIL antibodies, povetacicept (Novartis/Chinook), zigakibart (AstraZeneca), and sparsentan (Travere Therapeutics). Additionally, Jiangsu Hengrui Pharmaceuticals and Nanjing Sanhome Pharmaceutical have filed patents for their own anti-APRIL antibodies. UCB Biopharma has filed patents for anti-APRIL/BAFF bispecific antibodies.
Still have questions about the IgAN competitive landscape? Let PatSnap Eureka answer them instantly.
Ask Eureka About the IgAN PipelineMap Every Anti-APRIL Patent and Clinical Signal Before Your Competitors Do
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D and IP strategy in IgA nephropathy and beyond.
References
- Mathur M, et al. Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy. NEJM, 2023.
- Liu W, et al. APRIL-Targeted Therapy for IgA Nephropathy: Current Development and Future Perspectives. 2024.
- Visterra, Inc. Methods of Treating IgA Nephropathy with an Anti-APRIL Antibody (WO2023215516A1). 2023.
- CSL Vifor. Anti-APRIL Antibodies and Methods of Use (US20230340115A1). 2023.
- Novartis AG. Anti-BAFF/APRIL Bispecific Antibody and Uses Thereof in Treating IgA Nephropathy (WO2024201249A1). 2024.
- Radhakrishnan J, et al. Povetacicept (BION-1301) in IgA Nephropathy: Phase 2 Results and Phase 3 Design. 2024.
- AstraZeneca AB. Methods of Treating IgA Nephropathy with Zigakibart (WO2022147258A1). 2022.
- Rovin BH, et al. Sparsentan for IgA Nephropathy: Dual Endothelin-Angiotensin Receptor Antagonism. 2023.
- Boyd JK, et al. The Four-Hit Hypothesis in IgA Nephropathy and Therapeutic Targeting of Gd-IgA1 Production. 2022.
- Barratt J, et al. Inhibition of APRIL-mediated Signaling as a Novel Approach for Treating IgA Nephropathy. 2023.
- Schena FP, et al. Targeted Therapies in IgA Nephropathy: Emerging Pipeline and Competitive Landscape. 2024.
- Rizk DV, et al. Complement Inhibition in IgA Nephropathy: Targeting the Alternative and Lectin Pathways. 2023.
- ClinicalTrials.gov — IgA Nephropathy Active Trials Registry.
- NCBI PubMed — IgA Nephropathy APRIL BAFF Literature.
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform.
PatSnap Eureka searches patents and research to answer instantly.